Clinical trial NCT03970954: Low-dose Interleukin-2 in Women With Unexplained Miscarriages
Official title: Regulatory T-cell Induction by Low-dose Interleukin-2 in Women With Unexplained Repeated Spontaneous Early Miscarriages
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Recurrent Miscarriage
Keywords: Low-dose Interleukin-2
Miscarriage
Regulatory T cells
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
Collaborators: name: Iltoo Pharma
First posted: 2019-06-03
Enrollment: 18
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to demonstrate the ability of low dose IL-2 to stimulate peripheral blood Tregs of women with unexplained repeated early spontaneous miscarriages for development of a therapy to prevent fetal rejection by low dose IL-2.

Detailed description: About 1 to 3% of women of childbearing age have repeated early spontaneous miscarriages that may be related to parental chromosomal abnormalities, uterine abnormalities, hormonal causes, infectious etiology, thrombophilia ... When one of these known causes is excluded, it is unexplained miscarriages of which half would be due to an immunological deregulation of the mother causing a decrease of the tolerance to the fetus.

In this context, the stimulation of regulatory T cells (Tregs) by low dose IL-2 is a therapeutic option with a rational, preclinical and clinical data very favorable.

In humans, low dose IL-2 allows preferential activation of Tregs and is very well tolerated. Several therapeutic trials have shown its efficiencies.

These elements make it possible to envisage the development of a therapeutic to prevent fetal rejection by IL2-fd on the women with spontaneous miscarriages by an immunological deregulation.

Eligibility criteria: Inclusion Criteria:

* Woman with at least 5 consecutive early miscarriages less than 14 weeks of amenorrhea and unexplained after the usual check-up;
* Volunteer to participate in the trial and having given written consent after appropriate information.

Exclusion Criteria:

* Uterine or pelvic abnormality: uterine malformation, intracavitary fibroid, synechiae, polyp, hydrosalpinx;
* Balanced translocations in both spouses;
* Diabetes type I or II;
* Sickle cell disease;
* Contraindication to pregnancy;
* Constitutional or acquired thrombophilia (protein deficit C, S, ATIII, homozygous factor V or II deficiency, antiphospholipid syndrome, antithyroid antibodies positive, celiac disease, hyperhomocysteinemia);
* Ovarian insufficiency (AMH \<1 ng/ml); AFC \< 4
* Significant spermogram abnormalities and DNA fragmented more than 30%
* Active HIV or HCV infection;
* Main known contraindications to treatment with IL-2:
* Hypersensitivity to the active substance or to any of the excipients;
* Signs of progressive infection requiring antibiotic therapy;
* History of organ allograft;
* Pre-existing autoimmune disease;
* Leukocytes \<4000 / mm3; platelets \<100,000 / mm3; hematocrit \<30%;
* hepatic or renal insufficiency;
* depression;
* significant history or existence of a serious heart disease (in doubtful cases, perform a stress test);
* patients with autoimmune disease;
* patients with an infection (septicemia, bacterial endocarditis, septic thrombophlebitis, peritonitis and pneumonia);
* pregnancy;
* Treatment with immunomodulators, immunosuppressants (class L04A of the ATC classification), in particular systemic corticosteroids, as well as aspirin and low molecular weight heparin;
* No affiliation to a social security;
* Person who has already been included in this study or in another at the same time;
* Major incapacitated patient (tutorship / curatorship);
* Patient with an allergy to taking IL2-fd;
* Participants who would present professional risk factors (eg ionizing exposure);

Primary outcomes:
measure: Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)
timeFrame: At the day 38 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1]
measure: Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)
timeFrame: At the day 66 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
measure: Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)
timeFrame: At the day 94 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
measure: Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)
timeFrame: At the day 122 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
measure: Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)
timeFrame: At the day 150 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 11
Secondary outcomes:
measure: Variation of rate of blood circulating T regulator lymphocytes(expressed in absolute numbers)
timeFrame: At the day 38 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
measure: Variation of rate of blood circulating T regulator lymphocytes(expressed in absolute numbers)
timeFrame: At the day 66 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
measure: Variation of rate of blood circulating T regulator lymphocytes(expressed in absolute numbers)
timeFrame: At the day 94 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
measure: Variation of rate of blood circulating T regulator lymphocytes(expressed in absolute numbers)
timeFrame: At the day 122 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
measure: Variation of rate of blood circulating T regulator lymphocytes(expressed in absolute numbers)
timeFrame: At the day 150 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 11
Other outcomes:
Locations:
city: Paris
country: France
facility: Mekinian
state: Hopital Saint Antoine
city: Paris
country: France
facility: Bornes
state: Hopital Tenon
city: Paris
country: France
facility: Kayem
state: Hopital Trousseau
Study officials:
affiliation: Pitié Salpètrière APHP Paris
name: David Klatzmann, Pr
role: PRINCIPAL_INVESTIGATOR
affiliation: Saint Antoine APHP Paris
name: Arsene Mékinian, Dr
role: STUDY_DIRECTOR
affiliation: Trousseau APHP Paris
name: Gilles Kayem, Pr
role: STUDY_DIRECTOR
References: